PRESS RELEASES

4D Molecular Therapeutics Announces Presentation of Preclinical Data at the 6th International Update on Fabry Disease and Provides Clinical Update

- Novel vector, 4D-C102, demonstrates superior performance compared to commonly used AAV1, AAV8, and AAV9 - - Fabry product candidate, 4D-310, is on track for anticipated clinical trial initiation in 2020 - Superior transduction of 4DMT’s novel vector, 4D-C102, ...